Alembic Pharma Q2 Results: Net profit rises 12% to Rs 153 crore, revenue up 3%
Alembic Pharma reported a 12% YoY rise in Q2FY25 net profit to Rs 153 crore, driven by strong domestic and US market sales. Revenues grew 3% to Rs 1648 crore, while EBITDA declined 6%, with margins at 15.6%
By Viswanath Pilla, ET Bureau |
ETMarkets.com
Drug maker Alembic Pharma on Thursday reported Rs 153 crore net profit in Q2FY25, which is a 12% year-on-year (YoY) increase compared to corresponding period of previous year led by sales momentum in domestic formulation and US market.
The company reported Rs 133 crore in net profit in Q2FY23.
Revenues grew 3% to Rs.1648 crores in Q2FY25 compared to Rs 1595 crore last year.
The earnings before interest, tax, depreciation and amortization (EBITDA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 15.6% in Q2FY25.
The domestic formulation business that constitutes about 37% revenues rose 6% YoY to Rs 609 crore in Q2FY25. Alembic has a market share of 1.4% of the Indian pharma market and four brands with revenue of Rs 1 billion, according to IQVIA, September 2024 data. Around 13% of the product portfolio is under National List of Essential Medicine (NLEM) price control.
Animal health business grew 20% YoY to Rs 118 crore.
The US business that constitutes 29% rose 6% YoY to Rs 467 crore in Q2FY24 led by new launches and market share gain in few existing products.
The company said launches from new facilities to drive growth in upcoming quarters.
Ex-US international formulations grew 18% to Rs. 298 crores in the quarter.
The active pharmaceutical ingredient (API) business that constitutes 16% of revenues declined 15% YoY to Rs 274 crore due to pricing pressure.
"The company has focused on improving profitability, with new product launches in US market, we would expect to see stronger performance in the quarters ahead," said Pranav Amin, Pranav Amin is the Managing Director of Alembic Pharmaceuticals
The company reported Rs 133 crore in net profit in Q2FY23.
Revenues grew 3% to Rs.1648 crores in Q2FY25 compared to Rs 1595 crore last year.
The earnings before interest, tax, depreciation and amortization (EBITDA) declined 6% YoY to Rs 218 crore. The EBITDA margins stood at 15.6% in Q2FY25.
The domestic formulation business that constitutes about 37% revenues rose 6% YoY to Rs 609 crore in Q2FY25. Alembic has a market share of 1.4% of the Indian pharma market and four brands with revenue of Rs 1 billion, according to IQVIA, September 2024 data. Around 13% of the product portfolio is under National List of Essential Medicine (NLEM) price control.
Animal health business grew 20% YoY to Rs 118 crore.
ADVERTISEMENT
The US business that constitutes 29% rose 6% YoY to Rs 467 crore in Q2FY24 led by new launches and market share gain in few existing products.
The company said launches from new facilities to drive growth in upcoming quarters.
Ex-US international formulations grew 18% to Rs. 298 crores in the quarter.
The active pharmaceutical ingredient (API) business that constitutes 16% of revenues declined 15% YoY to Rs 274 crore due to pricing pressure.
ADVERTISEMENT
"The company has focused on improving profitability, with new product launches in US market, we would expect to see stronger performance in the quarters ahead," said Pranav Amin, Pranav Amin is the Managing Director of Alembic Pharmaceuticals
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Alembic Pharma Q2 Results: Firm posts Rs 137-crore net profitADVERTISEMENT
